[Management View]
DaVita reported adjusted operating income of $517 million for Q3 2025, aligning with internal expectations. The company emphasized strategic priorities such as technology investments, clinical platform enhancements, and AI solutions to drive long-term efficiencies and clinical advancements.

[Outlook]
DaVita reaffirmed its full-year adjusted operating income guidance of $2.035 billion to $2.135 billion and adjusted EPS of $10.35 to $11.15. The company anticipates a structural improvement in volume growth for 2026, driven by the non-recurrence of 2025 headwinds like flu, hurricane, and cyber incidents.

[Financial Performance]
- Adjusted operating income: $517 million (Q3 2025)
- Adjusted EPS: $2.51 (Q3 2025)
- Free cash flow: $604 million (Q3 2025)
- U.S. treatment volume: Declined by 1.5% YoY
- Revenue per treatment (RPT): Increased by $6 sequentially
- Patient care costs per treatment: Increased by $5 sequentially

[Q&A Highlights]
Question 1: How do you think volumes would have played out this year excluding the hurricane, cyber, and flu impacts?
Answer: The combined impact of these events was a 75 to 100 basis point headwind on 2025 volume. This includes both census and mistreatment rates.

Question 2: Is there optimism that mortality improvements can impact next year, or is it a slow, steady improvement over time?
Answer: Mortality improvements are expected to be steady over time, focusing on clinical protocols, fluid management, and medications like GLP-1s.

Question 3: How significant is the Medicare Advantage enrollment as a swing factor for 2026?
Answer: The Medicare Advantage enrollment and premium tax credit policy are significant swing factors due to their impact on payer mix and revenue.

Question 4: Can you comment on the potential growth for next year and the impact of technology investments on treatment growth?
Answer: A structural improvement of 50 to 75 basis points in 2026 growth relative to 2025 is expected. Technology investments may impact volume and cost structure, but specific impacts are uncertain.

Question 5: Is the $120 million headwind from premium tax credits still a good estimate?
Answer: Yes, the estimate remains $120 million over three years, with $40 million in year one, $70 million in year two, and $10 million in year three.

Question 6: What was the impact of the cyber attack and Mozark relationship on earnings?
Answer: The cyber attack primarily impacted volume, while the Mozark charge will largely eliminate its drag on the P&L next year.

Question 7: Can you discuss new patient starts and mortality trends in Q3?
Answer: New patient starts and mortality trends were within normal post-COVID bands, with no significant changes.

Question 8: What is the timing of IKC funds and the impact on Q4 guidance?
Answer: IKC timing remains difficult to predict, with revenue recognition dependent on information from payers and the federal government.

Question 9: What would drive the range of the implied Q4 guidance?
Answer: RPT and IKC are the primary variables. Q4 volume growth is expected to be positive, around 20 to 30 basis points year-over-year.

Question 10: What is the market share trend for 2025 excluding the cyber incident?
Answer: There is no meaningful shift in market share, with adjustments for the cyber incident impact.

[Sentiment Analysis]
Analysts' tone was inquisitive, focusing on volume recovery, technology investments, and policy impacts. Management remained confident in achieving full-year goals and highlighted long-term investments.

[Quarterly Comparison]
| Metric | Q3 2025 | Q2 2025 | YoY Change |
|-------------------------------|---------------|---------------|--------------|
| Adjusted Operating Income | $517 million | $526 million | -1.7% |
| Adjusted EPS | $2.51 | $2.55 | -1.6% |
| Free Cash Flow | $604 million | $610 million | -1.0% |
| U.S. Treatment Volume | -1.5% | -1.0% | -0.5% |
| Revenue per Treatment (RPT) | +$6 | +$5 | +$1 |
| Patient Care Costs per Treatment | +$5 | +$4 | +$1 |

[Risks and Concerns]
- Medicare Advantage enrollment and premium tax credit policy changes
- Timing of IKC revenue recognition
- Potential variability in payer mix and revenue per treatment

[Final Takeaway]
DaVita's Q3 2025 performance met internal expectations, with strategic investments in technology and clinical platforms poised to drive long-term efficiencies. The company remains focused on navigating policy and payer dynamics while reaffirming its full-year guidance. Looking ahead, DaVita anticipates a structural improvement in volume growth for 2026, driven by the non-recurrence of 2025 headwinds.